Frontiers in Pharmacology (May 2020)

Iron Promotes Dihydroartemisinin Cytotoxicity via ROS Production and Blockade of Autophagic Flux via Lysosomal Damage in Osteosarcoma

  • Ying Shen,
  • Ying Shen,
  • Ying Shen,
  • Bin Zhang,
  • Bin Zhang,
  • Bin Zhang,
  • Yanwei Su,
  • Yanwei Su,
  • Yanwei Su,
  • Shaikh Atik Badshah,
  • Shaikh Atik Badshah,
  • Xiaofei Wang,
  • Xin Li,
  • Xin Li,
  • Xin Li,
  • Yanru Xue,
  • Yanru Xue,
  • Yanru Xue,
  • Li Xie,
  • Li Xie,
  • Zhe Wang,
  • Zhe Wang,
  • Zhouqi Yang,
  • Zhouqi Yang,
  • Ge Zhang,
  • Peng Shang,
  • Peng Shang

DOI
https://doi.org/10.3389/fphar.2020.00444
Journal volume & issue
Vol. 11

Abstract

Read online

Osteosarcoma cellular iron concentration is higher than that in normal bone cells and other cell types. High levels of cellular iron help catalyze the Fenton reaction to produce reactive oxygen species (ROS), which promotes cancer cell proliferation. Dihydroartemisinin (DHA), a classic anti-malarial drug, kills plasmodium through iron-dependent ROS generation. In this research, we observed the anti-osteosarcoma effects and mechanisms of DHA. We found that DHA induced ROS production, caused mitochondrial damage, and activated autophagy via stimulation of the ROS/Erk1/2 pathway. As the storage site for a pool of ferrous iron, lysosomes are often the key organelles affected by drugs targeting iron. In this study, we observed that DHA induced lysosomal superoxide production, leading lysosomal membrane permeabilization (LMP), and autophagic flux blockage. By reducing or increasing cellular iron using deferoxamine (DFO) or ferric ammonium citrate (FAC), respectively, we found that DHA inhibited osteosarcoma in an iron-dependent manner. Therefore, iron may be a potential adjuvant for DHA in osteosarcoma treatment.

Keywords